A new clinical trial (June 2025) investigates ATR‑04, a microbiome-based topical therapy using engineered Staphylococcus epidermidis to treat EGFR inhibitor–related rashes. A breakthrough for side effect management in oncology. ATR‑04: Microbiome Medicine Tackling EGFR Inhibitor Skin Toxicities A…
Alessia Nobile
A groundbreaking May 2025 study published in Nature Communications challenges the long-standing belief of a sterile brain: microbial traces identified in human brain tissue. What are the implications for neuroscience and medicine? Does the Brain Host Bacteria? A Discovery That May Transform…
Alessia Nobile
EGFR and Lysosomes: Cell Biology Rewritten by a Single Receptor An April 2025 study unveils a novel role for the EGFR receptor in lysosomes: it activates mTORC1 without enzymatic function. Here’s why this marks a turning point for science and medicine. In university classrooms, EGFR is taught as a…
Alessia Nobile
